Colonic toxicity from pancreatins: A contemporary safety issue

Lancet

Volumn 353, Issue 9156, 1999, Pages 911-915

  Powell, C J ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EUDRAGIT; KREON; PANCREAS ENZYME; PANCREATIN; PANCRELIPASE;

COLON DISEASE; CYSTIC FIBROSIS; DRUG SAFETY; ENTERIC COATED TABLET; FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0033550999     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)02023-6     Document Type: Review

References (37)

1. Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343: 85-86.
2. Oades PJ, Bush A, Ong PS, Brereton RJ. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994; 343: 109
3. Campbell CA, Forrest J, Musgrove C. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994; 343:109.
4. Ong PS, Oades PJ, Bush A, Brereton RJ. Colonic stricture in a boy with cystic fibrosis. Post Grad Med J 1995; 345: 752-56.
5. Van Velzen D, Ball LM, Dezfulian AR, Southgate A, Howard CV. Comparative and experimental pathology of fibrosing colonopathy. Postgrad Med J 1996; 72 (suppl 2): S39-48.
6. Pawel BR, Chadarevian de J-P, Franco ME. The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Hum Pathol 1997; 28: 395-99.
7. Smyth RL, Ashby D, O'Hea U, et al. Fibrosing colonopathy in cystic fibrosis: results of a case-contol study. Lancet 1995; 346: 1247-51.
8. Knabe N, Zak M, Hansen A, et al. Extensive pathological changes of the colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343: 1230.
9. Freiman J, Fitzsimmons SC. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centres in the US. J Pediatr Gastroenterol Nutr 1996; 22: 153-56.
10. Schwartzenberg SJ, Wielinski CL, Shamieh I, et al. Cystic fibrosis-associated colitis and fibrosing colonopathy. J Pediatr 1995; 127: 565-70.
11. FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336: 1283-89.
12. Moss RL, Musemeche CA, Feddersen RM. Progressive pan-colonic fibrosis secondary to oral administration of pancreatic enzymes. Paediatr Surg Int 1998; 13: 168-70.
13. Hausler M, Meilicke R, Biesterfeld S, Heimann G. First adult patient with fibrosing colonopathy. Am J Gastroenterol 1998; 93: 1171-72.
14. Pohl M, Krackhardt B, Posselt HG, Lembcke B. Ultrasound studies of the intestinal wall in patients with cystic fibrosis. J Paediatr Gastroenterol Nutr 1997; 25: 317-20.
15. Posselt HG. Presentation on the questionnaire to cystic fibrosis centres in Germany. In: Fruhstorfer B, Heinz A, Berger D, Hilpert U, Kupferk K, eds. Consensus conference on the management of cystic fibrosis. Berlin: Spinger Verlag, 1995: 3-5.
16. Littlewood JM. Chairman's introduction. Postgrad Med J 1996; 72 (suppl 2): S2-3.
17. Stevens JC, Maguiness KM, Hollingsworth J, Heilman DK, Chong SKF. Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy. J Pediatr Gastroenterol Nutr 1998; 26: 80-84.
18. Anon. European Society of Toxicology Meeting, June, 1997, Aarhus, Denmark. Pharmacol Toxicol 1997; 80 (suppl 3): 62, 63, 70-72.
19. Shukla AJ. Polymethacrylates. In: Wade A, Weller PJ, eds. Handbook of pharmaceutical excipients. London: Pharmaceutical Press, 1994.
20. Ghanayem BI, Maronpot RR, Matthews HB. Ethyl acrylate-induced gastric toxicity: effect of single and repetitive dosing. Toxicol Appl Pharmacol 1985; 80: 323-35.
21. Ghanayem BI, Maronpot RR, Matthews HB. Ethyl acrylate-induced gastric toxicity: structure-toxicity relationships and mechanism. Toxicol Appl Pharmacol 1985; 80: 336-44.
22. Ghanayem BI, Maronpot RR, Matthews HB. Ethyl acrylate-induced gastric toxicity: development and recovery of lesions. Toxicol Appl Pharmacol 1986; 83: 576-83.
23. Frederick CB, Hazelton GA, Frantz JD. The histopathological and biochemical response of the stomach of male F344/N rats following two weeks of oral dosing with ethyl acrylate. Toxicol Pathol 1990; 18: 247-56.
24. Harrison PT. Proprionic acid and the phenomenon of rodent forestomach tumorigenesis: a review. Food Chem Toxicol 1992; 30: 333-40.
25. Gopinath C, Prentice DE, Lewis DJ. Atlas of experimental pathology: current histopathology. Vol 13. Lancaster: MTP Press, 1987.
26. Lee J, Ip W, Durie P. Is fibrosing colonopathy an immune mediated disease? Arch Dis Child 1997; 77: 66-77.
27. Trechot PA, Netter P, Moore N, Vidrequin A, Boissel P, Voltz C. Reasons for the removal of an enteric-coated slow-release potassium preparation from the market in France. Am J Gastroenterol 1990; 55: 330-31.
28. Jones R, Franklin K, Spicer R, Berry J. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 1995; 346: 499.
29. van Velzen D. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 1995; 346: 499-500.
30. Taylor CJ. Colonic strictures in cystic fibrosis. Lancet 1994; 343:615-16.
31. Taylor CJ, Steiner GM. Fibrosing colonopathy in a child on low-dose pancreatin. Lancet 1995; 346: 1106-07.
32. Bakowski MT, Prescott P. Patterns of use of pancreatic enzyme supplement in fibrosing colonopathy: implications for pathogenesis. Pharmacoepidemiol Drug Safety 1997; 6: 347-58.
33. O'Hare MM, McMaster C, Dodge JA. Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. J Pediatr Gastroenterol Nutr 1995; 21: 59-63.
34. MCA. Update - bowel strictures and high-potency pancreatins. Curr Probl Pharmacovigil 1994; 20: 13.
35. MCA. Report of committee on safety of medicines working party on pancreatins. Curr Probl Pharmacovigil 1995; 21: 11.
36. Murphy JL, Wotton SA, Bond SA, Jackson AA. Energy content of stools in normal healthy controls and patients with cystic fibrosis. Arch Dis Child 1991; 66: 495-500.
37. Lebenthal E. High-strength pancreatic exocrine enzyme capsules associated with strictures in patients with cystic fibrosis: "more is not necessarily better". J Pediatr Gastroenterol Nutr 1994; 18: 423-25.